Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Delafloxacin
Vancomycin
Ceftaroline Fosamil
Others
Segment by Application
Cellulitis
Abscess
Surgical Wounds
Traumatic Wound
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Furiex Pharmaceuticals, Inc.
GlaxoSmithKline plc
Melinta Therapeutics, Inc.
Debiopharm International S.A.
MerLion Pharmaceuticals Pte Ltd.
Durata Therapeutics, Inc.
Paratek Pharmaceuticals, Inc.
Cempra, Inc.
Abbott Laboratories, Inc.
Actelion Pharmaceuticals Ltd.
Albany Molecular Research, Inc.
Allergan plc.
AstraZeneca
Bayer AG
Macrolide Pharmaceuticals, Inc.
Merck & Co, Inc.
Pfizer, Inc.
Sanofi
Teva Pharmaceuticals Industries Ltd.
Zavante Therapeutics, Inc.